Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19

NCT04615871 on ClinicalTrials.gov · last registry update 2022-02-08

An unusually large phase 2: 400 participants, more than double the 110 typical for the stage. Its estimated completion date, 31 March 2022, has passed with no update to the record. Primary outcome, as filed: Composite of death or mechanical ventilation. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: UNKNOWN
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Vladimír Džavík
Sponsor type: Other
Enrollment: 400
Started: 2021-09-10
Primary completion: 2022-03-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Composite of death or mechanical ventilation

Conditions studied

Covid19 · Myocardial Injury

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.